Table 1.
Main characteristics of published studies
| Study | n | Design | Mean age (y) | Male (%) | Diabetics (%) | BMI (kg m−2) | Clinical setting | % of ST | Follow-up (months) | Platelet reactivity assay | % of poor responders | 192Q allele frequency (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bouman 2011a | 112 | Case-cohort | 61.2 ± 8.5 | 79.5 | 25.9 | 27.0 + 3.2 | 41 ST vs. 71 controls | 37 | 18 | LTA (ADP 20 μm) | NA | 66.9 |
| Bouman 2011b | 1982 | Cohort | 62.2 ± 10.2 | 71.3 | 24.3 | 27.1 + 4.3 | ACS | 2.2 | 12 | No | NA | 63.9 |
| Campo 2011 | 300/281 | Cohort | 66 ± 13 | 77.0 | 23.7 | 27.0 ± 4 | PCI (61% NSTEMI) | 1.3 | 12 | VerifyNow | 13 | 66.7 |
| Cayla 2011 | 123/246 | Case-cohort | 62.7 ± 12.2 | 80.5 | 25.2 | 26.6 ± 4.1 | ST vs. non-ST | 50 | – | No | – | 67.1 |
| Cuisset 2011 | 482 | Cohort | 63.0 ± 10 | 81.0 | 28.0 | 26.3 ± 4.0 | ACS | – | No | LTA (ADP 10 μm) and VASP | NA | 69.9 |
| Delaney 2012 | 693 | Case-control | 68.3 ± 11.7 | 63.5 | 34.8 | 30.3 ± 6.4 | MI and PCI patients | 1.7 | – | – | – | 69.0 |
| Dery 2011 | 213 | Cohort | 61.1 ± 9.8 | 83.1 | 9.8 | 28 ± 4.2 | 30 days post-PCI | – | – | LTA (ADP 5 μm), VASP | NA | 70.2 |
| Fontana 2011 | 538 | Cohort | 62 ± 12.2 | 81.9 | 21.2 | 26.5 ± 3.9 | Stable | – | – | LTA (ADP 20 μm), VASP | 49.6 (VAS P) | 70.8 |
| Hulot 2011 | 371 | Cohort | 40.3 ± 5.5 | 84.6 | 10.5 | 25.9 ± 4 | Stable young survivors of MI | 4.8 | 96 | VerifyNow | NA | 65.2 |
| Lewis 2011a | 566 | Cohort | 45.5 ± 13.2 | 48.7 | 0.9 | 27.0 ± 4.7 | Healthy subjects | – | – | LTA (ADP 20 μm) | NA | 68.0 |
| Lewis 2011b | 210 | Cohort | 64.3 ± 11.4 | 59.9 | 36.6 | 30.4 ± 6.6 | Non-emergent PCI | NA | 12 | LTA (ADP 20 μm) in 180 patients | NA | NA |
| Rideg 2011 | 189 | Cohort | 61.8 ± 8.4 | 61.4 | 37.6 | 29.4 ± 5.2 | Non-emergent PCI | 0.5 | 12 | LTA (ADP 5 μm) and VASP | NA | 70.9 |
| Sibbing 2011a* | 1524 | Cohort | 67.5 ± 10.5 | 77.4 | 28.2 | 27.5 ± 4.4 | PCI (67% stable) | – | – | MEA | 20 | 72.7 |
| Sibbing 2011b | 127/1439 | Case-control | 67.6 ± 10.5 | 77.5 | 29.0 | NA | Cases with ST | 8.1 | – | No | – | NA |
| Simon 2011 | 1538 | Cohort | 64.4 ± 13.1 | 74.7 | 29.7 | 27.4 ± 4.7 | ACS with PCI only | NA | 12 | – | – | 66.7 |
| Trenk 2011 | 760 | Cohort | 66.3 ± 9.2 | 78.3 | 24.3 | 27.7 ± 3.9 | Elective PCI | 2.1 | 12 | LTA (ADP 5 and 20 μm), FACS | NA | 70.5 |
| Tselepis 2011 | 74 | Cohort | 63.3 ± 8.6 | 70.3 | NA | NA | ACS | – | – | LTA (ADP 5 and 10 μm), VASP, FACS | 23 (at 5 days with VASP) | 70.3 |
ACS, acute coronary syndrome; ADP, adenosine diphosphate; LTA, light transmission aggregometry; MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; ST, stent thrombosis.
*
Used for platelet reactivity data only.